The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
- PMID: 15887287
- DOI: 10.1002/path.1787
The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
Abstract
p63 is a p53-related gene mapping to 3q28 that codes for multiple mRNA transcripts with (TA-p63) or without (DeltaN-p63) transactivating effects on genes that promote cell differentiation and apoptosis. We analysed p63 alterations by immunohistochemistry, quantitative real-time RT-PCR and FISH in a series of 45 follicular lymphomas (FL). None of the tumours showed immunoreactivity for the p40 antibody, which recognizes only the truncated isoforms of p63, or DeltaN-p63 mRNA expression. Immunoreactivity for the 4A4 antibody, which recognizes both the transactivating and the truncated p63 isoforms, was found in 5 +/- 5.5%, 6.85 +/- 4.88% and 33.2 +/- 22.31% of grade I, II and III FL cells, respectively (p < 0.0001). Quantitative RT-PCR analysis showed that all cases but one had TA-p63 mRNA levels higher than non-neoplastic lymphocytes, and that TA-p63 mRNA expression correlated significantly (r = 0.9194, p < 0.0001) with the prevalence of p63 immunoreactivity. FISH extra signals for the p63 gene were found in seven (23.3%) of the 30 cases analysed (0/6 grade I, 2/15 grade II and 5/9 grade III; p = 0.01937). Further hybridizations showed a pattern highly suggestive of chromosome 3 polysomy in six cases. One of these cases also bore extra copies of the p63 and bcl-6 genes. Co-localization of p63 and IgH signals was found in one case. No association between the prevalence of p63 immunoreactivity and extra p63 gene signals was detectable when the cases were dichotomized according to a p63 immunoreactivity threshold of 10%. Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells.
Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Similar articles
-
Differential expression of p63 isoforms in normal tissues and neoplastic cells.J Pathol. 2002 Dec;198(4):417-27. doi: 10.1002/path.1231. J Pathol. 2002. PMID: 12434410
-
TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53.Oncogene. 2006 Apr 13;25(16):2349-59. doi: 10.1038/sj.onc.1209270. Oncogene. 2006. PMID: 16331262
-
Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.Laryngoscope. 2004 Dec;114(12):2063-72. doi: 10.1097/01.mlg.0000149437.35855.4b. Laryngoscope. 2004. PMID: 15564824
-
p63 and epithelial biology.Exp Cell Res. 2006 Apr 1;312(6):695-706. doi: 10.1016/j.yexcr.2005.11.028. Epub 2006 Jan 9. Exp Cell Res. 2006. PMID: 16406339 Review.
-
p63: oncogene or tumor suppressor?Curr Opin Genet Dev. 2006 Feb;16(1):38-44. doi: 10.1016/j.gde.2005.12.001. Epub 2005 Dec 15. Curr Opin Genet Dev. 2006. PMID: 16359856 Review.
Cited by
-
A double dealing tale of p63: an oncogene or a tumor suppressor.Cell Mol Life Sci. 2018 Mar;75(6):965-973. doi: 10.1007/s00018-017-2666-y. Epub 2017 Oct 3. Cell Mol Life Sci. 2018. PMID: 28975366 Free PMC article. Review.
-
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors.Biomark Res. 2021 Jan 25;9(1):7. doi: 10.1186/s40364-021-00260-5. Biomark Res. 2021. PMID: 33494829 Free PMC article.
-
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.Cell Death Differ. 2011 Sep;18(9):1487-99. doi: 10.1038/cdd.2011.81. Epub 2011 Jul 15. Cell Death Differ. 2011. PMID: 21760596 Free PMC article. Review.
-
Role of p63 in Development, Tumorigenesis and Cancer Progression.Cancer Microenviron. 2012 Dec;5(3):311-22. doi: 10.1007/s12307-012-0116-9. Epub 2012 Jul 31. Cancer Microenviron. 2012. PMID: 22847008 Free PMC article.
-
The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia.Blood Adv. 2022 Apr 26;6(8):2646-2656. doi: 10.1182/bloodadvances.2021006348. Blood Adv. 2022. PMID: 35235952 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous